Drug Profile
Inavolisib - Genentech
Alternative Names: GDC 0077; RG 6114; RO-7113755Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Roche
- Class Amides; Amines; Antineoplastics; Aza compounds; Benzene derivatives; Fluorinated hydrocarbons; Imidazoles; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer; HER2 positive breast cancer
- Phase II Breast cancer; Ovarian cancer; Solid tumours
- Phase I Colorectal cancer; Squamous cell cancer
Most Recent Events
- 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
- 16 Feb 2024 MedSIR plans a phase II trial for Breast cancer (Combination therapy, Adjuvant Therapy) (PO) in 1st March 2024 (NCT05708235) (EudraCT2022-002616-24)
- 28 Dec 2023 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(In volunteers, In adults) in USA (IV)